January 23, 2020 - Fierce Pharma
The real estate impresario that built a chain of upscale drug recovery facilities is now jumping on a new trend. Brian O’Neil’s MLP Ventures says it is creating a CDMO and building a $1.1 billion gene and cell treatment manufacturing operation in a former GlaxoSmithKline site near Philadelphia.
The Center for Breakthrough Medicines will be located at The Discovery Labs, the 1.6 million-square-foot bioscience co-working space MLP is developing in the former GSK facilities is slated to occupy about 40% of that space.
January 22, 2020 - Contract Pharma
Ncardia
and
BlueRock Therapeutics
have entered an agreement covering process development technologies for the manufacture of induced pluripotent stem cell (iPSC)-derived cardiomyocytes. Bluerock gains access to Ncardia’s large-scale production processes and intellectual property for the production of iPSC-derived cardiomyocytes for therapeutic use.
“BlueRock is a leader in the field of cell therapy and our collaboration is a perfect match of mission and capabilities," said Stefan Braam, chief executive officer, Ncardia.This relationship allows us to utilize our experience in iPSC process development to help advance potential cell therapies for cardiac diseases."
January 22, 2020 - BioPharma Dive
Eli Lilly on Tuesday said it will invest about $470 million in building a new drug manufacturing plant in Durham, North Carolina, an expansion the Indianapolis pharma said would create some 460 jobs.
The facility will be located in Research Triangle Park, a hub for biomedical research in the state, and focus on the production of injectable medicines and delivery devices.
